{
  "id": "56c1f00cef6e39474100003e",
  "type": "factoid",
  "question": "Aleglitazar is agonist of which receptor?",
  "ideal_answer": "Aleglitazar is a balanced peroxisome proliferator-activated receptor-\u03b1/\u03b3 agonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22244809",
    "http://www.ncbi.nlm.nih.gov/pubmed/19515415",
    "http://www.ncbi.nlm.nih.gov/pubmed/22113345",
    "http://www.ncbi.nlm.nih.gov/pubmed/21114416",
    "http://www.ncbi.nlm.nih.gov/pubmed/21251281",
    "http://www.ncbi.nlm.nih.gov/pubmed/20837369",
    "http://www.ncbi.nlm.nih.gov/pubmed/20336066",
    "http://www.ncbi.nlm.nih.gov/pubmed/24157957",
    "http://www.ncbi.nlm.nih.gov/pubmed/24016490",
    "http://www.ncbi.nlm.nih.gov/pubmed/25407798",
    "http://www.ncbi.nlm.nih.gov/pubmed/24682069",
    "http://www.ncbi.nlm.nih.gov/pubmed/22514701",
    "http://www.ncbi.nlm.nih.gov/pubmed/26093872"
  ],
  "snippets": [
    {
      "text": "Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26093872",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Aleglitazar is a dual peroxisome proliferator-activated receptor \u03b1/\u03b3 agonist with favorable insulin-sensitizing and glucose-lowering actions, favorable effects on blood lipids, and an acceptable safety profile in short-time studies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26093872",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Coupled with the previous failure of several other peroxisome proliferator-activated receptor \u03b1/\u03b3 activators, this class now holds little promise for CV therapeutics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26093872",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aleglitazar is a dual agonist of peroxisome proliferator-activated receptors with insulin-sensitizing and glucose-lowering actions and favorable effects on lipid profiles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682069",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aleglitazar acts through balanced activation of peroxisome proliferator-activated receptors \u03b1 and \u03b3; warfarin is a commonly prescribed anticoagulant. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of the dual peroxisome proliferator-activated receptor-\u03b1/\u03b3 agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407798",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This Phase IIb safety study (AleNephro) in patients with stage 3 chronic kidney disease and type 2 diabetes, evaluated the renal effects of aleglitazar, a balanced peroxisome proliferator-activated receptor-\u03b1/\u03b3 agonist",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407798",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aleglitazar is a dual peroxisome proliferator-activated receptor (PPAR)-\u03b1/\u03b3 agonist in clinical development, designed to offer a balanced activation of PPAR-\u03b1 and PPAR-\u03b3",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22113345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The PPARalpha- and PPARgamma-related effects occurred over similar dose ranges, indicating that aleglitazar is a balanced agonist of the two receptor subtypes",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20336066",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aleglitazar is a dual peroxisome proliferator-activated receptor (PPAR)-\u03b1/\u03b3 agonist with a balanced activity (similar half-maximal effective concentrations) toward PPAR-\u03b1 and -\u03b3 that is in clinical development for the treatment of patients who have experienced an acute coronary syndrome and have type 2 diabetes mellitus",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22244809",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aleglitazar is a new, balanced dual peroxisome proliferator-activated receptor (PPAR)\u03b1/\u03b3 agonist designed to optimize lipid and glycemic benefits and minimize PPAR-related adverse effects",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20837369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor \u03b1/\u03b3 agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21251281",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19515415",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Effects of the dual peroxisome proliferator-activated receptor-\u03b1/\u03b3 agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407798",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Aleglitazar is a dual peroxisome proliferator-activated receptor \u03b1/\u03b3 agonist with favorable insulin-sensitizing and glucose-lowering actions, favorable effects on blood lipids, and an acceptable safety profile in short-time studies",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26093872",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study was performed to evaluate the effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor \u03b1/\u03b3 (PPAR\u03b1/\u03b3) agonist, on both lipid and glycemic parameters in obese, hypertriglyceridemic, insulin-resistant rhesus monkeys",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21251281",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This Phase IIb safety study (AleNephro) in patients with stage 3 chronic kidney disease and type 2 diabetes, evaluated the renal effects of aleglitazar, a balanced peroxisome proliferator-activated receptor-\u03b1/\u03b3 agonist",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407798",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evaluation of the dual peroxisome proliferator-activated receptor \ufffd/\ufffd agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24016490",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19515415",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Aleglitazar is a potent dual PPAR agonist with insulin-sensitizing and glucose-lowering actions and favorable effects on lipid profiles and biomarkers of cardiovascular risk. The AleCardio trial examines whether the addition of aleglitazar to standard medical therapy reduces the risk of cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome.STUDY DESIGN: AleCardio is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24016490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-\u03b1/\u03b3 agonist, aleglitazar, with tesaglitazar (a dual PPAR-\u03b1/\u03b3 agonist) or a combination of pioglitazone (Pio; PPAR-\u03b3 agonist) and fenofibrate (Feno; PPAR-\u03b1 agonist) in human hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22514701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aleglitazar, a dual PPAR-\u03b1/\u03b3 agonist, combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones.  To investigate the pharmacokinetic effects of co-administration of atorvastatin or rosuvastatin with aleglitazar.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21114416",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "peroxisome proliferator-activated receptor-\u03b1/\u03b3"
}